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Abstract
Background: The influence of genetic variation on complex diseases is potentially mediated through a range of
highly dynamic epigenetic processes exhibiting temporal variation during development and later life. Here we
present a catalogue of the genetic influences on DNA methylation (methylation quantitative trait loci (mQTL)) at
five different life stages in human blood: children at birth, childhood, adolescence and their mothers during
pregnancy and middle age.
Results: We show that genetic effects on methylation are highly stable across the life course and that developmental
change in the genetic contribution to variation in methylation occurs primarily through increases in environmental or
stochastic effects. Though we map a large proportion of the cis-acting genetic variation, a much larger component of
genetic effects influencing methylation are acting in trans. However, only 7 % of discovered mQTL are trans-effects,
suggesting that the trans component is highly polygenic. Finally, we estimate the contribution of mQTL to variation in
complex traits and infer that methylation may have a causal role consistent with an infinitesimal model in which many
methylation sites each have a small influence, amounting to a large overall contribution.
Conclusions: DNA methylation contains a significant heritable component that remains consistent across the lifespan.
Our results suggest that the genetic component of methylation may have a causal role in complex traits. The database
of mQTL presented here provide a rich resource for those interested in investigating the role of methylation in disease.
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Background
Epigenetic mechanisms play a central role in the regula-
tion of cellular processes by influencing genomic activity
[1]. DNA methylation, defined as the covalent bonding
of a methyl group to a cytosine in the context of a CpG
dinucleotide, is an important component of these
mechanisms in mammals. Canonically, DNA methyla-
tion typically represses transcription, which can occur by
inhibiting the binding of transcription factors or by
recruiting DNA binding proteins that remodel chro-
matin structure. Consequently, the establishment and
maintenance of DNA methylation patterns are crucial for
normal cellular function and developmental processes and,
indeed, these patterns are highly heterogeneous at different
life stages [2] and between different tissue types [3].
Genome-wide DNA methylation can be considered to
be a large set of measurable traits (one per CpG site) in
which variation can arise from environmental [4],
stochastic [5] or genetic [6] perturbations, and there is
growing evidence that DNA methylation could mediate
the relationship between these processes in influencing
complex diseases [7]. An important step in understand-
ing the processes underpinning DNA methylation is
mapping the genetic factors that influence its variation.
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A recent study estimated that almost 20 % of reliably
assayed variation in blood DNA methylation is heritable
and that 50 % of CpG sites showed evidence of a signifi-
cant genetic component [8]. A different perspective is
provided by a study looking at the most variably methyl-
ated regions between neonates, which found 25 % were
best explained by genotype alone and 75 % by a combin-
ation of genotype and environment [9]. Another large
study showed that DNA methylation variation in adipose
tissue was highly heritable (h2median = 0.34) and that
shared environmental effects correlated with metabolic
phenotype-associated CpGs [10]. Heritability of CpG
methylation levels in whole blood in young people has
also been shown to correlate highly with stability of
methylation at the same sites in later life [11]. However,
those studies that have attempted to map genetic effects
influencing DNA methylation (methylation quantitative
trait loci (mQTL)) have so far only explained a small pro-
portion of the genetic variance that is estimated to exist
and it is evident that much larger sample sizes will be re-
quired to map the majority of the predicted genetic effects.
One can address the question of how genetic variation
influences DNA methylation in a number of ways and
here we focus on three specific research avenues. First,
the genetic architecture of methylation variation can
provide information about the level of complexity that
underlies population-level differences. This can be exam-
ined by (a) estimating the proportion of explanatory
common genetic variation (mQTL) that occurs close to
the methylation site (in cis) versus the proportion that
occurs elsewhere in the genome (in trans), and (b) the
level of polygenicity of the genetic component for cis
and trans regions.
Second, in characterising and mapping mQTL it is of
interest to know the extent to which genetic effects are
stable over time. Because epigenetic change is a corner-
stone of mammalian development, elucidating whether
genetic effects have a consistent influence across the life
course or are specific to certain developmental windows
is important for gauging the extent to which mQTL
could be involved in epigenetic restructuring and per-
turbation of developmental trajectories.
Third, a comprehensive catalogue of mQTL can be
used to investigate (a) whether those regions of methyla-
tion that are influenced by genetic variation are likely to
be inert or are involved in cellular function and (b) if
these elements are functional, then to what extent do
mQTL influence complex disease as a consequence of
their influence on DNA methylation.
Here we present a comprehensive genome-wide cis
and trans mQTL longitudinal analysis in blood DNA at
three time points in the life course of a large number of
participants in the Avon Longitudinal Study of Parents
and Children (ALSPAC) [12] and two time points in the
life course of their mothers [13], in the form of an online
searchable database (http://www.mqtldb.org/). We assess
the stability of mQTL across the life course and identify
the biological pathways in which they function. We
evaluate the relationship of mQTL with other down-
stream phenotypes, including gene expression, traits and
diseases, and quantify the contribution made by mQTL
to genetic variance in several common complex diseases
that have previously been the subject of genome-wide
association studies (GWAS).
Results
Cis and trans mQTL mapping
The ARIES dataset [14] represents DNA methylation
levels collected at five different time points across the
life course from individuals in ALSPAC: in young people
we collected samples at birth (cord blood, n = 771),
childhood (n = 834) and adolescence (n = 837); in their
mothers we sampled during pregnancy (n = 764) and in
middle age (n = 742) (Additional file 1: Table S1). We
performed an exhaustive whole-genome mQTL analysis
by testing approximately 8.3 million common single-
nucleotide polymorphisms (SNPs) against each reliable
CpG probe (395,625 out of 485,577) in each time point
(Additional file 1: Table S2). After conservative multiple
testing correction (p < 1 × 10−14) we identified between
24,262 and 31,729 sentinel associations at each time
point (Table 1; Additional file 1: Table S3). Approxi-
mately 93 % of the mQTL were acting in cis (defined as
within ±1 Mb of the CpG probe on the basis of previous
a previous report [15] and our own observation of the
distribution of SNP/CpG distances, although definitions
of cis in the literature vary widely from a few hundred
base pairs [16] to 1 Mb [17, 18]).
We also performed conditional analysis which identi-
fied between 2705 and 5446 further mQTL at each time
point that showed secondary, tertiary and quaternary
effects also acting in cis (Additional file 1: Figure S1),
giving 28,946–39,833 mQTL discovered at each time
point influencing a total of 43,897 CpG sites across the
genome (Table 1, Fig. 1a). The effect sizes as difference
in median proportion methylated between homozygote
groups is presented in Additional file 1: Figure S2.
Genetic architecture of methylation variation
DNA methylation may be influenced by both genetic
and environmental factors. To address the question of
the relative contribution of genetic variation we used
genomic restricted maximum likelihood (GREML) [19].
Here we estimated how much of the total variation in
each methylation probe was captured by all 1.1 million
common HapMap3 [20] tagging SNPs (minor allele fre-
quency (MAF) > 0.01) to estimate what is known as the
SNP heritability. Although the standard error is high for
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any one probe, when performed on all reliable probes at
five time points this analysis enabled us to estimate the
distribution of genetic contribution to methylation vari-
ation (SNP heritability) and how it varies over time. In
addition, for each probe we partitioned the genetic
variance into two components, the first using cis SNPs
only and the second using trans SNPs only.
The results demonstrate that although the majority of
mQTL act in cis, the majority of estimated genetic vari-
ation that influences methylation levels is acting in trans
Table 1 Number of mQTL and associated CpGs reaching the significance threshold for each time point
Counts Birth Childhood Adolescence Pregnancy Middle age
Sentinel mQTL
Cisa 24,262 31,729 30,294 29,038 27,043
Transb 1979 2658 2442 2394 2144
Conditionally independentc 2705 5446 5040 4454 3463
Total mQTL 28,946 39,833 37,776 35,886 32,650
Total unique CpGs 27,387 36,705 34,886 33,344 30,676
aNumber of CpG sites with a cis SNP
bNumber of independent (±1 Mb) trans effects
cNumber of mQTL further detected after performing conditional analysis
Fig. 1 Temporal pattern of mQTL. a The total number of cis and trans mQTL discovered at each time point. b Total bars represent the SNP heritability
at each time point. Each bar is split into genetic variation due to common SNPs acting in cis (blue) and trans (green). Cis and trans variation is further
divided into the proportion that is explained by mapped SNPs (p < 1 × 10−14). c The proportion of discovered mQTL at a specific time point that
replicate at p < 1 × 10−7 in each of the other time points. Darker colours correspond to lower replication rates
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(Fig. 1b). This applies even if we extend the definition of
cis to include the entire chromosome (data not shown).
Variance explained by detected mQTL
Having partitioned the phenotypic variance of each CpG
probe into cis-acting genetic variance, trans-acting gen-
etic variance and environmental variance (which in-
cludes any genetic variance not captured by 1.1 million
HapMap3 SNPs), we then went on to estimate how
much of the genetic variation was ‘explained’ by the
mQTL that we had detected in our association analyses.
We estimated that the discovery mQTL detected in our
association analysis explained over half of the proportion
of total cis variation, whereas the trans mQTL explained
less than 1 % of total trans variation. This result is con-
sistent with the hypothesis that genetic perturbation
close to the CpG site tends to have large effects whereas
the complex network of regulatory interactions and a
large mutational target size makes the trans component,
on average, highly polygenic.
Stability of genetic effects over time
DNA methylation changes in response to environmental
exposures. We addressed the question of how stable the
mQTL effects were over time by estimating the rate of
replication of discovery mQTL from one time point in all
other time points. Fig. 1c and Additional file 1: Figure S3
show that the proportion that replicated at a threshold of
p < 1 × 10−7 was typically in excess of 95 %, although the
rate of replication of post-birth discovery mQTL in the
birth time point was consistently lower (84–86 %).
The distributions of estimated SNP heritabilities
illustrate that average SNP heritability gradually falls
from 0.24 in childhood to 0.21 at middle age (Fig. 1a,
b). A regression of SNP heritability on age indicated a
reduction of heritability of −0.0009 per year from
childhood to adulthood (–0.0009, se=1.6e–5). There
are two simple explanations for this observation: first,
that the influence of genetic variation is reducing
over time; or second, that the influence of environ-
mental or stochastic perturbations is increasing over
time. In the former case we would expect that the
average coefficient of variation of methylation to de-
crease over time due to there being fewer genetic fac-
tors, whereas in the latter case we would expect it to
increase due to more environmental factors or higher
stochasticity. The latter explanation is supported by a
clear increase (3.0 %, standard error 0.015 %) in the
average coefficient of variation of methylation from
childhood to middle age (data not shown).
In addition, while replication of mQTL from middle
age to childhood is high, replication of mQTL from
childhood is lower in later time points (Fig. 1c). To-
gether this suggests that genetic effects are largely stable
and that environmental or stochastic perturbation is
gradually increasing over the life course, leading to lower
SNP heritability estimates and lower power to detect
mQTL as age increases. Two caveats to these observa-
tions are that the later two time points are different indi-
viduals from the earlier ones and they are comprised
exclusively of women.
The stability of genetic effects is surprisingly high given
the observational correlations of DNA methylation be-
tween different time points (Additional file 1: Figure S4).
However, we observe that the mean correlation of methy-
lation probes that have at least one significant mQTL is
substantially higher than the average value (e.g. for all
probes r ¼ 0:09 and for mQTL probes r ¼ 0:31 when
comparing childhood with adolescence; Additional file 1:
Figure S5).
Long range influences of methylation levels
In contrast to what has been seen in expression quanti-
tative trait loci (eQTL) studies, there is little evidence of
individual mQTL influencing many CpG sites across the
genome, with the vast majority of trans mQTL in our
data just representing a single or small number of
associations (Additional file 1: Figure S6). To gauge the
extent to which methylation levels were influenced by
CpG sites elsewhere in the genome, we performed a
mediation analysis testing for mediation of trans mQTL
effects by cis methylation. Mediation analyses are
particularly susceptible to measurement error in the
mediator (which will attenuate estimates of mediation).
However, we provide some evidence that, amongst
mQTL with both cis and trans effects, a proportion
demonstrate some degree of mediation of the trans
association by cis CpG sites. Additional file 1: Figure S7
presents this mediation analysis comparing a regression
of trans CpG on SNP to a regression of trans CpG on
(SNP + cis CpG). Whilst a large number of sites follow
the y = x diagonal (providing little evidence of mediation),
a proportion deviate from this line, showing that if the
effects of cis methylation are taken into account, the trans
association is attenuated. This non-independence between
cis and trans effects at these loci does not prove a causal
effect of cis methylation on trans methylation. To deter-
mine the likely impact of measurement error on this ana-
lysis, we present simulations of the effect of measurement
error in the cis methylation variable in Additional file 1:
Figure S8, which illustrates that our observed results are
likely to underestimate the true extent of potential medi-
ation in the presence of measurement error.
Functional annotation
If mQTL are functionally important, they are likely to be
distributed differentially across genomic features. To
address this question, we analysed both mQTL and
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mQTL-associated CpG sites to determine their distribu-
tion across genomic regions. The distribution of DNA
methylation at mQTL-associated CpGs in different con-
texts (genic features, CpG islands, shelves and shores) is
illustrated in Additional file 1: Figures S9 and S10. This
illustrates consistency in distributions between time
points, but with notable differences between locations
(consistent with observations by Shi et al. [21]).
The distribution of cis and trans mQTL across genic
features at each time point (adjusted for overall represen-
tation within each feature) is presented in Fig. 2a–c. More
than 65 % of trans associations were trans-chromosomal.
Higher densities of trans-associated SNPs appear to occur
on chromosomes 16, 17 and 19, illustrated in the circos
bar charts in Fig. 2d showing density of associated CpGs
and SNPs, but these do correspond closely with regions of
higher gene density. The SNP heritability estimated by
common trans SNPs was, on average, consistent for
methylation levels at different genomic features, but there
was a substantial relative increase of cis genetic influ-
ence on methylation levels at regulatory regions com-
pared with coding regions (Fig. 2e).
Regional association plots for the top 25 cis associations
at each time point are presented in Additional file 1:
Figure S11, demonstrating a range of different patterns of
methylation depending on linkage disequilibrium and cor-
relation of methylation across the surrounding region.
There is little evidence of individual mQTL influencing
many CpG sites across the genome, with the vast majority
of trans mQTL in our data just representing a single or
Fig. 2 Genomic distribution of mQTL. a Distribution of mQTL across genomic features; b distribution of mQTL-associated CpG sites across CpG islands;
c distribution of mQTL-associated CpG sites across genic features. d Circos plot illustrating trans mQTL at birth (see Additional file 1: Figure S5 for other
time points). From the outside: chromosomes, −log10(p value) for association (red points), density of mQTL (blue bars), density of associated
CpGs (green bars), density of genes (gray bars), trans associations between SNP and CpG (lines). e Average estimated cis (top) and trans (bottom) SNP
heritability for methylation levels at different genomic features. Bar heights show mean heritability for each genomic feature. Error bars show standard
error of the mean heritability. Horizontal lines indicate the mean heritability across all features. UTR untranslated region
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small number of associations. However, this is very likely
to reflect a lack of power to detect effects in the current
sample size.
Overlap between our mQTL and eQTL reported previ-
ously by the GTEx consortium [22] is illustrated in
Additional file 1: Figure S12. Amongst cis QTL more loci
are both eQTL and mQTL than mQTL only. In a gene
ontology comparison of our mQTL with the eQTL re-
ported by Westra et al. [23], enrichment for genes from all
mQTL results showed little evidence of informative enrich-
ment (Additional file 1: Figure S13 and S14), but we found
that cis mQTL also reported as eQTL are enriched for
tissue development terms, whilst trans mQTL reported as
eQTL are enriched for terms related to plasma membrane
and cell periphery (Additional file 1: Figure S15).
Influence of mQTL on disease
Though it is clear that the genetic component of methy-
lation variation is substantial, the broad influence of
variation in methylation on distal traits and disease out-
comes is yet to be established. Observational associa-
tions between methylation and outcome are insufficient
to ascertain causality. An alternative approach is to test
if the cis mQTL that are likely to have direct effects on
methylation levels also influence complex traits. To test
this we partitioned the SNP heritability of seven complex
traits in the Wellcome Trust Case Control Consortium
(WTCCC) [24] data into a component for cis mQTL
and a component for all HapMap3 [20] tagging SNPs.
For comparison we compared our results against two
different null hypotheses: is the variance explained by
the mQTLs more than would be expected by chance
(a) from the same number of SNPs sampled from genic
regions and (b) if we sample the same number of SNPs to
have the same distribution of genomic annotations as the
mQTLs (Fig. 3a; Additional file 1: Figure S16)? In both
cases we match our null SNPs to our mQTLs on allele fre-
quency and linkage disequilibrium (LD) structure also.
Our results suggest that, for Crohn's disease, hyperten-
sion and rheumatoid arthritis, the proportion of SNP
heritability attributed to mQTL was greater than ex-
pected under the null hypothesis that their contribution
was solely due to residing within a particular set of gen-
omic annotations (null hypothesis ‘b’). However, note
that the evidence for these results is weak (p > 0.05) if
multiple testing is taken into account using a Bonferroni
correction. An additional limitation of this analysis is
that the WTCCC controls (used for all seven diseases)
were normal population samples and, therefore, may
have included some cases. We next used our discovery
mQTL to test for enrichment of low p values in publicly
available GWAS results from large meta-analyses
(Fig. 3b). We observed evidence that mQTL were
more enriched for low p values in GWAS results than
(a) randomly sampled genic SNPs and (b) mQTL
annotation-matched SNPs for 9 and 8 out of 33 complex
traits (Bonferroni corrected p < 0.05/33), respectively.
Those complex traits showing enrichment for cis mQTL
in GWAS results against both null hypotheses were
Alzheimer’s disease, schizophrenia, low-density lipopro-
tein cholesterol, bone mineral density and blood pressure.
These results suggest that there may be a genetic influence
via methylation on downstream complex traits and that it
is likely that very many CpG sites contribute to complex
traits, each contributing only a small effect.
Discussion
We present a large-scale analysis of blood mQTL in
children and their mothers at multiple time points
through the life course. We found that, whilst methyla-
tion itself is not highly stable over time, the effects of
mQTL are surprisingly consistent, both within the same
individuals and across a generation. This stability is con-
sistent with another study that found significant overlap
in mQTL between developmental stages (in addition to
between ancestral groups and tissue types) [9]. Average
SNP heritability of DNA methylation exceeded 0.2 at all
time points, with trans effects estimated to account for
the majority of this heritability. This is consistent with
previously reported total heritability on the Illumina
Infinium HM450 array of 0.187 [8]. However, the
proportion of trans heritability explained by our trans
mQTL is much smaller than the proportion of cis herit-
ability explained by our cis mQTL. This is most likely
due to polygenic trans effects, with many trans mQTL
explaining too little variance for us to detect in a sample
of this size, whilst cis effects have relatively larger mono-
or oligogenic effects. The effect sizes of our trans mQTL
also tend to be smaller (Additional file 1: Figure S2),
although a minority still have effects exceeding a 10 %
difference in proportion methylated. Overall our effect
sizes exceeded 2 % difference in proportion methylated
for more than 50 % of mQTL and greater than 5 %
methylated for more than 25 % of mQTL. Whilst this
means that some of our mQTL have a potentially small
biological effect, these results will still be of value in
Mendelian randomization analysis [25] and analysis of
the genetic architecture of DNA methylation.
We observed two interesting patterns when we exam-
ined the similarities in genetic effects on methylation at
different time points. Firstly, fewer mQTL were discov-
ered at birth and estimates of heritability were lower at
birth than in childhood. Secondly, heritability of methy-
lation and the total number of mQTL decrease with
increasing age (with the exception of birth). The poten-
tial explanations for these observations are that either
genetic effects change over time or environmental effects
change over time. An increase in overall variation in
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Fig. 3 mQTL enrichment in diseases and traits. a Contribution of mQTL identified at each time point to variance of WTCCC common diseases
bipolar disorder (BD), coronary artery disease (CAD), Crohns disease (CD), hypertension (HT), rheumatoid arthritis (RA), type 1 diabetes (T1D) and
type 2 diabetes (T2D). Red dots represent the component of a trait’s genetic variance attributable to cis-acting mQTL SNPs with significance levels
of p < 1 × 10−14, on the liability scale, excluding chromosome 6. Black points depict the point estimates of SNP heritability estimates under the
null hypotheses of SNPs coming from genic regions (left plot) or SNPs with the same proportion of genic features as the mQTLs (right plot).
P values relate to the proportion of the null estimates that surpass the mQTL estimates. b Enrichment analysis of cis-acting mQTL SNPs with
significance levels of p < 1 × 10−14 in large-scale GWAS summary statistics for 33 complex traits. The solid horizontal line denotes empirical p value of
0.05 and the dotted line shows the threshold after correcting for multiple testing. Red bars are based on a null of genic SNPs, blue bars on a null of
mQTL-matched SNPs. HDL = high-density lipoprotein cholesterol, LDL = low-density lipoprotein cholesterol, BMD = bone mineral density, FN = femoral
neck, LS = lumbar spine, BMI = body mass index, AMD = age-related macular degeneration and ALS = amyotrophic lateral sclerosis
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methylation over time suggests that the latter is more
likely, with the environment having a relatively greater
influence around birth and then later in life. This is con-
sistent with the postulated period of methylation plasti-
city in utero and the epigenetic drift observed through
the life course. The largest proportion of time point-
specific effects were at birth (cord blood), with adoles-
cence and middle age having the lowest proportion. This
suggests that a small proportion of mQTL may play a
more important role during early development, with
their relative importance diminishing later in life.
Regional association patterns for cis mQTL varied
widely between loci, with some showing distinct blocks
of mQTL SNPs and associated CpGs (i.e. SNPs associat-
ing with many CpGs within the same LD block but very
few outside). This apparent alignment of SNP LD blocks
with methylation blocks may simply represent the short-
range functional effect of SNPs on CpG methylation,
with a number of SNPs in LD affecting a number of
nearby CpG sites. Other loci show a less distinct pattern
of association, with different CpGs associating with
different, but overlapping, sets of SNPs.
We observed some evidence that mQTL are enriched
in 5′ and 3′ untranslated regions compared with
intronic and intergenic regions, whilst the mQTL-
associated CpGs tend to be more frequent upstream of
the transcription start site. With respect to CpG islands
these mQTL-associated sites are enriched in north and
south CpG island shores. Whilst we don’t have other
QTL data from the same samples for direct comparison,
interestingly Banovich et al. [26] report notable overlaps
of mQTL with QTL for other regulatory features such as
histone modifications, DNase I hypersensitivity, chroma-
tin access and expression levels. Although we don’t have
direct measurements of expression to perform eQTL
analyses, we did perform a comparison of our mQTL
with the GTEx eQTL data [22]. The approximately 5 %
of GTEx eQTL that we report as mQTL is not incon-
sistent with the observation from a study in fibroblasts
that found 12 % of genes with an eQTL have a nearby
mQTL [27], although Banovich et al. [26] found that,
amongst eQTL within 3 kb of a methylation probe,
approximately 25 % were also mQTL.
In an additional analysis we found evidence that some
trans SNP–CpG associations may be mediated by cis
methylation. A recent mQTL study with a greater sam-
ple size than ours found a limited number of mQTL
affecting multiple (up to 19) sites [17]. Although we
observed a number of such cases, many trans effects do
not show evidence of cis mediation. However, our lim-
ited power to detect such mediation mechanisms and
the possibility that measurement error reduces the ap-
parent extent of mediation should be taken into account
when interpreting these findings. These observations are
consistent with a previous report based on lung tissue
[21] and underline the complexity of mQTL effects.
We found no evidence of SNPs affecting methylation
at a large number of sites, with the majority of our trans
mQTL representing just one SNP–CpG association. This
contrasts with observations in eQTL analysis which
suggest some SNPs impact on the regulation of a large
number of transcripts as ‘master regulators’ [28]. The
difference between mQTL and eQTL in this context
aligns with our observation that there is only limited
overlap between published blood eQTL [23] and our
blood mQTL (discussed in more detail above). A previ-
ously reported study of mQTL and eQTL amongst loci
associated with bipolar disorder also found orthogonality
between the two types of QTL [29]. Grundberg et al.
[10], profiling adipose tissue from 648 twins, revealed
that 28 % of CpGs were associated with nearby SNPs
and, when overlapping them with adipose eQTL from the
same individuals, they found that 6 % of the loci played a
role in regulating both gene expression and DNA
methylation. In contrast, a systems analysis of ~418 K
SNPs with ~23 K CpG sites and ~16 K expression probes
using blood from 148 individuals found evidence using cis
eQTL and mQTL to support a causal model in which
genotype affects methylation, which in turn affects expres-
sion [30]. However, the same study did not investigate
trans mQTL. There is, therefore, little evidence at this
stage to suggest either that there are mQTL master regu-
lators or that eQTL master regulators act on expression
via methylation. Thus, whilst methylation is known to in-
fluence gene expression, we find limited overlap between
mQTL and published eQTL and no evidence of ‘master
regulators’ in mQTL, suggesting a more complex relation-
ship than the simple SNP–methylation–expression model,
consistent with the recently reported findings of the
Epigenomics Roadmap Consortium [31].
Our results support a stable effect of genetic variation
on methylation across the life course, with common
SNPs accounting for approximately 20 % of variance in
methylation (with the caveat that cord blood is quite dif-
ferent in cellular composition from peripheral blood).
One important question is whether mQTL play a func-
tional role in disease. One previous study has indicated
potential roles for population-differential mQTL in age
of menarche, hepatitis B infection and HIV control [18],
whilst another has reported potential contributions of
mQTL to autoimmune disease (although they didn’t
formally analyse enrichment) [18]. Our analyses suggest
that mQTL are relevant to common diseases and traits,
accounting for a significant proportion of the heritability
of Crohn's disease, hypertension, rheumatoid arthritis
and type 1 diabetes. Our observations of a potential role
in autoimmune disease seem consistent with those of
Lemire et al. [17], although it is crucial to consider the
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potential that autoimmune genotype may drive mea-
sured DNA methylation through cellular heterogeneity.
The enrichment of mQTL in autoimmune diseases is
unlikely to be driven by large effects and long-range LD
in the major histocompatibility complex (MHC) region
because reanalysis excluding chromosome 6 returned
the same conclusion. Whilst this observation does not
prove causality, it suggests two important phenomena.
First, it provides a plausible role of methylation in medi-
ating some of the effects of common genetic variation
on disease and is consistent with one of the first mQTL
analyses to use the Illumina Infinium HM450 array, which
demonstrated enrichment of mQTL among disease-
associated loci [21]. Second, it suggests that if methylation
influences complex traits, then this is likely through
variation at many genomic loci, with each locus having a
small effect.
Limitations
Methylation data were only available in peripheral blood
from ALSPAC participants, so we were unable to com-
pare results between tissues (interestingly, mQTL have
been reported to be enriched for CpG sites that are vari-
able between tissues [32]). In addition, cord blood is not
directly equivalent to peripheral blood. Cellular hetero-
geneity can account for differences in methylation be-
tween samples, affecting different CpG sites to different
extents; we had no directly measured cell count data
available but applied an established method [33] to ad-
just for the potential confounding influence of these ef-
fects. However, this method was optimised on adult
samples (not children). It may also not be an appropriate
approach for use in cord blood, which may explain some
of the differences we observe between birth and other
time points.
DNA was extracted from different blood sample types,
which could potentially affect methylation measure-
ments, although in seeking to test this possibility we
illustrate in Additional file 1: Figure S17 that sample
type does not appear to stratify the top principal compo-
nents of DNA methylation.
The adults in our sample are all female, so one may
wish to consider the generalizability of the reported
findings to adult males when interpreting data.
Some probes on the Illumina Infinium HM450 array
are known to be affected by a range of factors, including
underlying SNPs [34]; we filtered out the most severely
affected but recommend that this is taken into account
when interpreting and subsequently utilising the data we
have generated.
Whilst the number of mQTL we report in Table 1 dif-
fers from those in other publications (varying from 49
[35] to 52,708 [17] or more cis mQTL), it is important
to note that these numbers rely on arbitrary thresholds,
are susceptible to power and heavily influenced by defi-
nitions of cis and trans.
We note that even though there was generally good
agreement in overall results between our two null
models (null SNPs sampled from genic regions and null
SNPs sampled from the same distribution of genic anno-
tations as the true mQTLs), the enrichment p values
were quite sensitive to the null model used. We re-
commend caution in performing and interpreting such
enrichment analyses.
Conclusions
We demonstrate that genetic effects on methylation levels
are highly stable over time and that methylation variation
increases over time, most likely due to increased environ-
mental or stochastic influences. We also provide evidence
that methylation may play a mediating role in the
influence of genetic variation on complex traits. We are
releasing the results from our mQTL analysis in the form
of an open database (http://www.mqtldb.org/) to encour-
age consistent publication and integration of results from
other studies.
Methods
Study sample
Samples were drawn from the Avon Longitudinal Study of
Parents and Children [12, 13]. Blood from 1018 mother–
child pairs (children at three time points and their
mothers at two time points) were selected for analysis as
part of the Accessible Resource for Integrative Epigenomic
Studies (ARIES, http://www.ariesepigenomics.org.uk/)
(Additional file 1: Table S1) [14]. Numbers of samples
surviving the imposed quality control (QC) thresholds
at each time point are shown in Additional file 1:
Table S2. Sample selection was on the basis of sample
availability at all of the chosen time points in
mother–child pairs. Cord blood and peripheral blood
samples (whole blood, buffy coats, white blood cells
or blood spots) were collected according to standard
procedures.
Methylation assays
Following DNA extraction, samples were bisulphite con-
verted using the Zymo EZ DNA Methylation™ kit (Zymo,
Irvine, CA, USA). Following conversion, genome-wide
methylation was measured using the Illumina Infinium
HumanMethylation450 (HM450) BeadChip. The arrays
were scanned using an Illumina iScan, with initial quality
review using GenomeStudio. During the data generation
process a wide range of batch variables were recorded in a
purpose-built laboratory information management system
(LIMS). The LIMS also reported QC metrics from the
standard control probes on the HM450 BeadChip for each
sample. Samples failing QC were excluded from further
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analysis and the assay repeated. Data points with a low
signal:noise ratio (detection p > 0.01) or with methylated
or unmethylated read counts of 0 were also excluded from
analysis. As an additional QC step genotype probes on the
Ilumina Infinium HM450 array were compared between
samples from the same individual at different time points
and against SNP-chip data (HM450 probes clustered using
k-means) to identify and remove any sample mismatches.
Methylation data were normalised in R with the
wateRmelon package [36] using the Touleimat and Tost
[37] algorithm to reduce the non-biological differences be-
tween probes. Data were then rank-normalised to remove
outliers and regressed on all covariates plus bisulphite-
converted DNA (BCD) plate batch to remove potential
batch effects (with missing values set to probe mean).
Genotyping assays
The ARIES participants were previously genotyped as
part of the larger ALSPAC study, with QC, cleaning and
imputation performed at the cohort level before extrac-
tion of the subset comprising ARIES. ARIES participants
are of European white ancestry and homogeneous com-
pared with HapMap reference populations (Additional
file 1: Figure S18).
Children were genotyped using the Illumina Human-
Hap550 quad genome-wide SNP genotyping platform
(Illumina Inc., San Diego, CA, USA) by the Wellcome
Trust Sanger Institute (WTSI; Cambridge, UK) and the
Laboratory Corporation of America (LCA, Burlington,
NC, USA). Individuals were excluded on the basis of in-
correct gender assignment, abnormal heterozygosity
(<0.320 or >0.345 for WTSI data; <0.310 or >0.330 for
LCA data), high missingness (>3 %), cryptic relatedness
(>10 % identity by descent) and non-European ancestry
(detected by multidimensional scaling analysis). Follow-
ing QC, the final directly genotyped dataset contained
500,527 SNP loci.
Mothers were genotyped using the Illumina
human660W-quad genome-wide SNP genotyping plat-
form (Illumina Inc., San Diego, CA, USA) at the
Centre National de Génotypage (CNG; Paris, France).
Individuals were excluded based on non-European
ancestry, missingness, relatedness, gender mismatches and
heterozygosity. PLINK (v1.07) [38] was used to carry out
quality control measures on an initial set of 10,015 sub-
jects (including non-ARIES ALSPAC participants) and
557,124 directly genotyped SNPs. Following QC, the final
directly genotyped dataset contained 526,688 SNP loci.
Imputation was performed to increase the SNP density
for all genotyped mothers and children combined. Geno-
types were phased together using ShapeIt (version 2,
revision 727) and then imputed against the 1000
Genomes reference panel (phase 1, version 3, phased using
ShapeIt version 2, December 2013, using all populations)
using Impute (v2.2.2). Genotypes were filtered to have
Hardy–Weinberg equilibrium p > 5 × 10−7, MAF >1 % and
imputation info score >0.8. Best guess genotypes were
used for subsequent analysis. The final imputed data-
set used for the analyses presented here contained
8,074,398 loci.
Genotype/methylation association tests
Summary details of samples, SNPs, CpGs and covariates
included in association tests are presented in Additional
file 1: Table S2. Each SNP in the imputed datasets was ana-
lysed against all CpG sites in the Illumina Infinium HM450
array with the exception of those failing QC and those re-
ported to map to more than one location (N = 19,834) or to
contain a genetic variant at the CpG site (N = 74,182) [34].
We performed a post hoc test for analysis of non-specific
probes which determined that there was no enrichment of
cross-hybridising probes in our results. We opted for post
hoc annotation of potential probe effects within our results
database for the remaining potentially problematic CpG
sites (N = 229,983) [34]. The final number of probes ana-
lysed was 395,625. Preliminary association analysis of SNPs
with CpG sites was performed using an additive model
(rank-normalised CpG methylation on SNP allele count)
using Matrix eQTL [39] in order to perform the computa-
tionally demanding task of estimating 16 trillion associa-
tions. Analyses were batched by SNP chromosome and
sample time point for parallel analysis on the University of
Bristol High Performance Computing (HPC) cluster. SNP
effects from this analysis that were p < 1 × 10−7 were then
taken forward for re-analysis in PLINK1.07 to perform
exact linear regression including covariates. Covariates
included in all analyses were age (excluding birth), sex
(children only), the top ten ancestry principal components,
bisulphite conversion batch and estimated white blood cell
counts (using an algorithm based on differential methy-
lation between cell types [33]). Methylation at each CpG
site was regressed on these covariates and residuals taken
forward for regression on SNP genotype. To report the
number of mQTL, we used a conservative threshold of 1 ×
10−14. All associations below 1 × 10−7 were stored and are
available in our online mQTL database (http://www.
mqtldb.org/). Analysis on rank-normalised data results in
effect sizes that are not directly interpretable on the original
scale. Additional file 1: Figure S2 illustrates the effect size
distributions observed in our data.
Without access to an appropriate replication sample,
we performed all subsequent enrichment and down-
stream analysis using only cis mQTL with p < 1 × 10−14
(Additional file 1: Table S3) to reduce the possibility of
including false positives (unless otherwise stated). We
consider results below p < 1 × 10−14 in a single time
point to provide informative evidence of association on
the basis that this corresponds to a 0.2 % false positive
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rate after a Bonferonni correction for the number of
tests based on directly genotyped SNPs and directly
assayed CpG sites. We define replication in additional
time points to be associations at p < 1 × 10−7 because
typically we are testing in the order of 30,000 associa-
tions for replication and on the basis that these are sup-
ported by their combination with the evidence at other
time points through the life course.
Code availability
Code to run comparable mQTL analyses with ARIES
data is available under the GNU GPL (v3) license at
https://github.com/MRCIEU/ariesmqtl.
Conditional mQTL analysis
Linkage disequilibrium is expected to cause many
mQTL to be represented by multiple tag SNPs. We
used the conditional analysis implementation in GCTA
[19, 40] to determine the most representative independent
loci associated with each CpG site. We used the summary
statistics from the results of our PLINK analysis (i.e. any
SNP–CpG pair with a p ≤ 1 × 10−14 at any time point) and
entered them into a stepwise model using individual level
genotype data to determine whether they independently
account for association with the CpG site. Independent
signals with p < 1 × 10−14 are considered significant.
Patterns of methylation across genomic features and time
The distribution of DNA methylation across CpG sites
in different genic and CpG island regions was analysed
using annotations from the Illumina Infinium HM450
manifest file (v1.2). Each probe was assigned to an anno-
tation category (e.g. 5′ UTR, 3′ UTR, gene body, CpG
island, etc.), the median methylation beta (proportion
methylation) for that probe was calculated and then the
distribution of these medians across mQTL-associated
CpG sites in a category was plotted in a histogram.
To characterise the temporal pattern of methylation, the
correlation of methylation between each pair of time
points was calculated for each probe. The distribution of
correlation coefficients (r2) was plotted in a histogram for
each pair of time points. A null distribution of correlation
for each pair was derived by randomising the sample order
for one of the pair of time points, and similarly plotted as
a histogram of correlation coefficients.
Patterns of mQTL across genomic features and time
The distribution of mQTL-associated CpG sites was
analysed using annotations from the Illumina Infinium
HM450 manifest file (v1.2). The proportion of CpG
probes falling into each annotation category was plotted
in a bar chart to evaluate the distribution across differ-
ent genomic features. A similar approach was used for
mQTL SNPs, which were annotated with features using
the Variant Effect Predictor [41] (all associated SNPs
were included).
SNP heritability estimation of methylation probes
In order to estimate the proportion of the variation in
CpG probes that is due to genetic variation, we used
SNP heritability analysis for each probe (after filtering)
at each time point. This was performed using genomic
restricted maximum likelihood (GREML) as imple-
mented in GCTA (v1.24). The same covariates were
fitted here as they were for the mQTL mapping analysis.
Only unrelated individuals were used in these analyses
(genetic relatedness <0.05) in order to obtain a population-
based ‘SNP’ heritability estimate, which is typically an
underestimate of true heritability in complex traits be-
cause the magnitude of the estimate is limited to the
proportion of all genomic variation that is captured by the
SNPs on the genotyping array. In this case we used
HapMap3 [20] SNPs with MAF >0.01 and imputation
quality score >0.8 (1,171,463 SNPs after filtering). The
SNP heritability was estimated for each probe using two
variance components, the first generated using only SNPs
within ±1 Mb of the CpG site (the cis component) and the
second generated using all remaining SNPs (the trans com-
ponent), such that var(y) = var(g_cis) + var(g_trans) + var(e),
where the genetic variance due to all SNPs var(g) = var(gi_
cis) + var(g_trans), and var(g)/var(p) is the total SNP herit-
ability for a probe at a particular time point. The same
analysis was repeated for each probe at each time point.
We then make a distinction between ‘explained’ and
‘unexplained’ genetic variation (Fig. 2b). Some propor-
tion of the total estimated SNP heritability has been ‘ex-
plained’ by the detected mQTLs, estimated by summing
the R2 values for each conditionally significant associ-
ation at p < 1 × 10−14 for a particular probe at a particu-
lar time point. Thus, we term the remaining genetic
variation ‘unexplained’. The ‘explained’ genetic variation
was estimated for both the cis and trans genetic
components.
Proportion of trait variance explained by mQTL
In order to ascertain if mQTL contribute to variance in
disease liability, a mixed model analysis was performed
to calculate the proportion of the trait variance that
could be explained by mQTL and non-mQTL in pub-
licly available data from the first WTCCC publication
[24]. The variance partitioning model:
yi ¼ μþ gi;1 þ gi;2 þ ei
was fitted using REML as implemented in GCTA (v1.24)
software [19]. Here, yi is the phenotype of individual
i, gi,1 is their genetic value due to mQTL, gi,2 is their
genetic value due to all HapMap3 [20] SNPs that were
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not identified as mQTL and ei is their residual value. To
avoid results being influenced by MHC, both gi,1 and gi,2
were estimated excluding all SNPs on chromosome 6.
This analysis was performed for seven traits (bipolar dis-
order, Crohn’s disease, type 1 diabetes, type 2 diabetes,
coronary heart disease, hypertension, rheumatoid arthritis)
using the WTCCC data [24]. The WTCCC data under-
went the same quality control procedure described in [42].
Specifically, the data were split into seven case-control
datasets where the controls were common across all traits;
each dataset was filtered for MAF >0.01, genotype miss-
ingness <0.002, Hardy–Weinberg equilibrium p > 0.01 and
any SNPs with differential missingness between cases and
controls (p < 0.05) were removed. This left approximately
230,000 SNPs for each dataset. Pairwise genomic similarity
was then estimated using scaled SNP similarity and any
individual pairs with genomic relatedness >0.025 were re-
moved. Principal components were estimated from the
SNP data after removing regions of long-range LD and
pruning to low LD and five rounds of outlier removal were
used whereby if any individual had a value of mean ± 5
standard deviations in any of the first 20 components they
were removed. Imputation was performed to 1000 Ge-
nomes reference panel (phase 1, version 3, release Decem-
ber 2013) in two stages: first, haplotypes of the WTCCC
samples were estimated jointly using ShapeIt2 and then
imputation was performed using Impute2. Then, gi,2 was
estimated using only the imputed SNPs that were present
in the HapMap3 reference. To test if the mQTLs detected
in ARIES made disproportionately large contributions to
SNP heritability in the WTCCC datasets, we used only cis
mQTL with p < 1 × 10−14 at any time point that were then
LD pruned, leaving 29,805 SNPs in total. Generating an
appropriate null distribution against which to compare
the point estimate of the mQTL variance component in
this analysis is important because the mQTL variance
component may have been contaminated by variance due
to genic SNPs rather than directly due to mQTL alone.
To test for this possibility, we generated two different
‘null’ experiments. First, we sampled 29,805 SNPs that
were within ±500 kb of a gene (‘genic SNPs’), matching
the SNPs to have the same LD and allele frequency distri-
butions as the mQTLs and performing the entire analysis
again, but instead of using mQTLs, gi,1 was constructed
using these sampled SNPs. This was performed 100 times
to get a distribution of estimates under the null hypothesis
that proximity to genic regions is sufficient to explain the
influence of mQTLs on the trait. Second, the same was
done except instead of sampling from genic regions spe-
cifically, the null SNP set was generated to have the same
number of SNPs in 5′ UTR, 3′ UTR, intronic, intergenic,
upstream, downstream and unannotated regions of the
genome (‘mQTL annotation-matched SNPs’). All SNP
heritability estimates were transformed from the observed
to the liability scale using the trait prevalence estimates
used in [43]. Sex and the first 20 genetic principal compo-
nents were included as covariates in all analyses.
Mediation of trans mQTL effects by cis methylation
Potential mediation of trans mQTL effects by cis methy-
lation has been previously reported [21]. This type of
analysis is particularly susceptible to measurement error
in the cis (mediating) CpG methylation variable so re-
quires cautious interpretation. For all trans associations
we took the estimate of association from a linear regres-
sion of B ~ G, and then performed a second linear re-
gression B ~ G + Kx, where B is methylation at the trans
CpG site, G is the genotype (or allele score if more than
one independent cis association) and K is methylation at
the cis CpG site. Reduction in regression coefficient for
genotype when cis CpG methylation was added to the
model was evaluated as an estimate of potential mediation
(given the limitations of measurement error). We esti-
mated the likely impact of measurement error by perform-
ing a series of analyses in which we added increasing
levels of simulated measurement error (multiplication by
random values sampled from a normal distribution with
mean 1 and a given standard deviation).
Enrichment analysis for mQTL in GWAS results
To test if the mQTL were enriched for low p values in
previously published GWAS results, the following proced-
ure was performed. Only independent mQTL with cis
effects of p < 1 × 10−14 obtained from the conditional ana-
lysis and then filtered to remove SNPs with LD r2 > 0.1
were used to test for enrichment. We collected data from
a set of 33 complex traits from online sources. All
available mQTL were extracted from each trait and
Fisher's method was used to estimate a combined p value
for each trait:
χ22k ∼ −2
Xk
i¼1
ln pi
In order to compare these p values to a realistic null
distribution, the same procedure was performed but
using 10,000 random draws of the same number of SNPs
from (a) genic regions or (b) mQTL annotation-matched
SNPs. In both cases SNPs were also matched to the
mQTLs on allele frequency and number of proxies to
adjust for LD structure. In order to match on LD, each
mQTL was given an LD score by calculating the number
of SNPs that were in LD r2 > 0.8 and the same was done
for each of the candidate genic SNPs (approximately
200,000 genic SNPs). A null distribution for each GWAS
trait was generated by performing this procedure 1000
times, each time making a new random draw of genic
SNPs matched for allele frequency and LD. Empirical
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p values were generated by simply finding the rank of
the meQTL p value among the 1000 null p values.
Gene ontology enrichment
mQTL SNPs were mapped to the nearest gene (by
genomic coordinate) using the Variant Effect Predictor
and lists of unique gene names were analysed for enrich-
ment of gene ontology (GO) terms relative to a human ref-
erence using the gene ontology function (‘go’) in the
Orange bioinformatics add-on (‘Orange.bio’, http://orange.-
biolab.si/download/). CpG sites associated with mQTL
were similarly (but separately) tested for GO term enrich-
ment using the Illumina gene-name annotations for each
CpG site. Analyses were repeated for time point-specific
loci and those common to all time points. Potentially
enriched GO terms (biological function) were plotted
using REVIGO [44], where strength of evidence for en-
richment (−log10(p value)) is proportional to size.
Comparison of blood mQTL with blood eQTL
Previously reported blood eQTL [22] were downloaded
from http://www.gtexportal.org/ and compared with
mQTL discovered at each time point to determine over-
lap. Cis QTL were considered to be shared if the same
SNP was reported to be associated at p < 1 × 10−14 in
mQTL data and p < 2.5 × 10−7 in eQTL data (the re-
ported GTEx threshold). For GO analyses we compared
our mQTL data with blood eQTL from Westra et al.
[23] as these data enabled us to evaluate enrichment of
common QTLs for both cis and trans; however, a lack of
data prevented us from comparing the numeric overlap
between the Westra et al. eQTL and our mQTL.
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Written informed consent has been obtained from all
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obtained from the ALSPAC Ethics and Law Committee
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Availability of data and materials
A mQTL database containing all results from this study
is available online at http://www.mqtldb.org, which in-
cludes both search functionality and full download of all
results at p < 1 × 10−7 using Matrix eQTL and GCTA.
Data are also available for download at doi:10.5523/
bris.r9bxayo5mmk510dczq6golkmb.
All data used in this study were provided to the
authors by the ALSPAC cohort study via their standard
Access Policy. Data are available to other bona fide
researchers on the same basis; for details please see
http://www.bristol.ac.uk/alspac/researchers/data-access/.
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